Anti-PD-1 therapy failed in a CXCL13-null mouse model of BLCA, whereas the wild-type model showed a good response (59), and the treatment with a combination of CXCL13 and anti-PD-1 successfully retarded tumor growth in another mouse model of OV (60). This evidence concerns the gene CXCL13 and neoplasm.